What is Janux Therapeutics's change in deferred revenue?

Janux Therapeutics (JANX) reported change in deferred revenue of $46.27M in Q1 2026.

What is the long-term trend for Janux Therapeutics's change in deferred revenue?

Over 3 years (2021 to 2025), Janux Therapeutics's change in deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from -$2.14M to $0.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

Janux Therapeutics JANX Change in Deferred Revenue

Change in Deferred Revenue at other companies

Regeneron PharmaceuticalsREGN

$99.6M+463%

Arcus BiosciencesRCUS

-$17M+39.3%

ImmunomeIMNM

$0+100%

CRISPR TherapeuticsCRSP

-$427K+48.2%

Other financials

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

See full

Market cap$889.15M-36.3%

Enterprise value$858.89M-36.2%

P/S64.8×-84.8×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's change in deferred revenue?: Janux Therapeutics (JANX) reported change in deferred revenue of $46.27M in Q1 2026.
What is the long-term trend for Janux Therapeutics's change in deferred revenue?: Over 3 years (2021 to 2025), Janux Therapeutics's change in deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from -$2.14M to $0.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.